Companies Dominating the Genetic Testing Landscape
- Genentech Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sorenson Genomics
- Abbott Molecular
- Bayer AG
- Biocartis
- BioHelix
- Quest Diagnostics
- Exact Sciences Corporation
- HTG Molecular Diagnostics, Inc.
- PacBio
- GeneDx Holdings Corp.
- BioAro Inc.
- ProPhase Labs, Inc.
The quality and quantity of offerings from the market is evolving with the integration of AI and machine learning (ML). Thus, key players in this field are meticulously engaging their resources to cultivate such advanced portfolio. For instance, in March 2025, GeneDx launched an AI-based decision support tool, Multiscore, to leverage the capabilities of its interpretation platform. The embedded gene ranker is specifically designed to provide faster and more efficient clinical analysis. These revolutionary findings and creations are propelling growth and productivity in this sector and attracting more MedTech pioneers to invest in more innovation cohorts. Such key players are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Currently in 2025, the industry revenue of genetic testing is estimated at USD 24.25 billion.
The global genetic testing market was anticipated to increase from USD 22.74 billion in 2024 to USD 73.99 billion by 2037, demonstrating a CAGR of around 9.5% throughout the forecast timeline, from 2025 to 2037.
Asia Pacific industry is anticipated to account for largest revenue share of 36% by 2037, impelled by growing healthcare sector in the region.
The major players in the market include Genentech Inc., Sorenson Genomics, Abbott Molecular, Bayer AG, Biocartis, BioHelix, Quest Diagnostics, Exact Sciences Corporation, HTG Molecular Diagnostics, Inc., PacBio.
